Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Abstract: The design of the waveform covariance matrix for beampattern matching in colocated multiple-input multiple-output (MIMO) radars represents a challenging problem because of its large number ...

Abstract: Aimed at achieving low detent force and minimal permanent magnet usage, this paper discusses a novel design of a Primary Modular Twice Offset Alternating Pole Permanent Magnet Linear Motor ...